Ligand Pharmaceuticals reported $4.44M in Interest Expense on Debt for its third fiscal quarter of 2021.

Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
Interest Expense On Debt Change
Amgen AMGN:US $ 296M 15M
Arena Pharmaceuticals ARNA:US $ 1.03M 0.02M
Baxter International BAX:US $ 36M 1M
Bristol Myers Squibb BMY:US $ 328M 2M
Clovis Oncology CLVS:US $ 8.79M 0.02M
Dicerna Pharmaceuticals DRNA:US $ 0M 0M
Eli Lilly And LLY:US $ 83.6M 3.3M
Endo International Ordinary Shares ENDP:US $ 142.99M 1.35M
Flexion Therapeutics FLXN:US $ 6.29M 1.11M
Gilead Sciences GILD:US $ 250M 6M
Harsco HSC:US $ 16M 0.02M
Immunogen IMGN:US $ 2.75M 0.83M
Insmed INSM:US $ 11.24M 926K
Karyopharm Therapeutics KPTI:US $ 8.01M 3.01M
Lannett LCI:US $ 14.22M 1.01M
Ligand Pharmaceuticals LGND:US $ 4.44M 0.44M
Pacira Pharmaceuticals PCRX:US $ 7.33M 0.31M
Pfizer PFE:US $ 325M 9M
Rigel Pharmaceuticals RIGL:US $ 1.32M 0.44M
Teva Pharmaceutical Industries TEVA:US $ 232M 8M
Veracyte VCYT:US $ 0.06M 0M